Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinsonian Disorders | 10 | 2023 | 226 | 4.700 |
Why?
|
| Stroke | 20 | 2023 | 276 | 3.970 |
Why?
|
| Brain | 16 | 2023 | 1663 | 3.440 |
Why?
|
| Alzheimer Disease | 13 | 2023 | 2118 | 3.110 |
Why?
|
| Cognitive Dysfunction | 9 | 2023 | 1065 | 2.540 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2022 | 53 | 2.230 |
Why?
|
| Cerebrovascular Disorders | 4 | 2023 | 134 | 1.800 |
Why?
|
| Aged, 80 and over | 28 | 2023 | 4853 | 1.710 |
Why?
|
| Aged | 43 | 2023 | 9262 | 1.700 |
Why?
|
| Brain Ischemia | 6 | 2020 | 63 | 1.600 |
Why?
|
| Female | 56 | 2023 | 15708 | 1.520 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 61 | 1.510 |
Why?
|
| Male | 54 | 2023 | 15273 | 1.470 |
Why?
|
| Humans | 69 | 2023 | 28408 | 1.350 |
Why?
|
| Dementia | 4 | 2023 | 574 | 1.330 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 264 | 1.250 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 77 | 1.110 |
Why?
|
| Hypertension | 8 | 2023 | 244 | 1.080 |
Why?
|
| Atherosclerosis | 3 | 2023 | 55 | 1.070 |
Why?
|
| Aging | 11 | 2023 | 1549 | 1.060 |
Why?
|
| Risk Factors | 24 | 2023 | 2408 | 1.060 |
Why?
|
| Neuropsychological Tests | 6 | 2023 | 1226 | 1.050 |
Why?
|
| Dementia, Vascular | 2 | 2016 | 45 | 1.040 |
Why?
|
| Disease Progression | 5 | 2021 | 717 | 0.990 |
Why?
|
| tau Proteins | 4 | 2023 | 235 | 0.980 |
Why?
|
| Incidence | 15 | 2022 | 773 | 0.980 |
Why?
|
| Independent Living | 4 | 2023 | 318 | 0.930 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2023 | 110 | 0.920 |
Why?
|
| Stroke Rehabilitation | 2 | 2019 | 25 | 0.910 |
Why?
|
| Cardiovascular Diseases | 10 | 2018 | 372 | 0.880 |
Why?
|
| Limbic Encephalitis | 1 | 2023 | 12 | 0.860 |
Why?
|
| Amyloid beta-Peptides | 4 | 2023 | 327 | 0.850 |
Why?
|
| Motor Disorders | 1 | 2023 | 23 | 0.840 |
Why?
|
| Disabled Persons | 2 | 2023 | 125 | 0.820 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1384 | 0.790 |
Why?
|
| Iran | 18 | 2021 | 32 | 0.780 |
Why?
|
| Executive Function | 2 | 2015 | 115 | 0.770 |
Why?
|
| Prefrontal Cortex | 3 | 2023 | 137 | 0.740 |
Why?
|
| Exercise | 4 | 2023 | 473 | 0.700 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2021 | 17 | 0.700 |
Why?
|
| Cerebral Hemorrhage | 7 | 2023 | 108 | 0.700 |
Why?
|
| Health Status | 2 | 2021 | 224 | 0.700 |
Why?
|
| Mobility Limitation | 1 | 2021 | 94 | 0.680 |
Why?
|
| White Matter | 1 | 2021 | 134 | 0.680 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 113 | 0.660 |
Why?
|
| Child Development | 1 | 2020 | 75 | 0.660 |
Why?
|
| Vision, Ocular | 1 | 2019 | 1 | 0.660 |
Why?
|
| Beta Rhythm | 1 | 2019 | 3 | 0.660 |
Why?
|
| Eyeglasses | 1 | 2019 | 3 | 0.660 |
Why?
|
| Mental Health | 1 | 2021 | 122 | 0.650 |
Why?
|
| Agnosia | 1 | 2019 | 9 | 0.650 |
Why?
|
| Visual Perception | 1 | 2019 | 30 | 0.650 |
Why?
|
| Blood Pressure | 2 | 2020 | 207 | 0.640 |
Why?
|
| Brain Infarction | 1 | 2020 | 75 | 0.640 |
Why?
|
| Cohort Studies | 14 | 2022 | 1926 | 0.640 |
Why?
|
| Motor Activity | 3 | 2019 | 329 | 0.630 |
Why?
|
| Gait | 1 | 2023 | 412 | 0.630 |
Why?
|
| Cognition | 4 | 2023 | 1352 | 0.610 |
Why?
|
| Sex Characteristics | 1 | 2018 | 118 | 0.570 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2017 | 9 | 0.570 |
Why?
|
| Upper Extremity | 1 | 2017 | 64 | 0.550 |
Why?
|
| Age Factors | 7 | 2021 | 781 | 0.530 |
Why?
|
| Middle Aged | 29 | 2023 | 9254 | 0.520 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2015 | 27 | 0.510 |
Why?
|
| Autopsy | 4 | 2021 | 343 | 0.500 |
Why?
|
| Aspirin | 1 | 2015 | 84 | 0.480 |
Why?
|
| Triglycerides | 3 | 2022 | 61 | 0.470 |
Why?
|
| Case-Control Studies | 11 | 2023 | 593 | 0.430 |
Why?
|
| Metabolic Syndrome | 4 | 2018 | 62 | 0.420 |
Why?
|
| Receptors, Estrogen | 2 | 2023 | 60 | 0.410 |
Why?
|
| Parkinson Disease | 4 | 2023 | 851 | 0.410 |
Why?
|
| Canada | 4 | 2015 | 51 | 0.360 |
Why?
|
| Obesity | 4 | 2019 | 321 | 0.330 |
Why?
|
| Adult | 18 | 2023 | 8097 | 0.330 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 274 | 0.320 |
Why?
|
| Prospective Studies | 9 | 2023 | 1805 | 0.320 |
Why?
|
| Time Factors | 4 | 2019 | 1490 | 0.310 |
Why?
|
| Waist Circumference | 4 | 2019 | 35 | 0.310 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 1858 | 0.310 |
Why?
|
| Cognition Disorders | 3 | 2016 | 1003 | 0.310 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 390 | 0.280 |
Why?
|
| Recovery of Function | 2 | 2019 | 300 | 0.270 |
Why?
|
| Disability Evaluation | 2 | 2019 | 289 | 0.270 |
Why?
|
| Language | 1 | 2006 | 71 | 0.250 |
Why?
|
| Treatment Outcome | 6 | 2021 | 3615 | 0.250 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 352 | 0.240 |
Why?
|
| Neurofibrillary Tangles | 2 | 2023 | 193 | 0.240 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 932 | 0.240 |
Why?
|
| Waist-Hip Ratio | 5 | 2019 | 14 | 0.240 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 608 | 0.240 |
Why?
|
| Hospitalization | 1 | 2007 | 323 | 0.240 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1216 | 0.230 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2023 | 19 | 0.220 |
Why?
|
| Risk Assessment | 4 | 2021 | 676 | 0.220 |
Why?
|
| Binge Drinking | 1 | 2023 | 10 | 0.210 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 25 | 0.210 |
Why?
|
| RNA | 1 | 2023 | 37 | 0.210 |
Why?
|
| Smoking | 3 | 2020 | 176 | 0.210 |
Why?
|
| Cerebrum | 1 | 2023 | 11 | 0.210 |
Why?
|
| Opium | 1 | 2022 | 1 | 0.200 |
Why?
|
| Hand Strength | 1 | 2023 | 60 | 0.200 |
Why?
|
| Cholesterol | 1 | 2022 | 64 | 0.200 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 64 | 0.200 |
Why?
|
| Spinal Cord | 1 | 2022 | 85 | 0.200 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2021 | 1 | 0.190 |
Why?
|
| Motor Cortex | 1 | 2021 | 17 | 0.190 |
Why?
|
| Migraine Disorders | 1 | 2021 | 19 | 0.190 |
Why?
|
| Life Style | 2 | 2020 | 201 | 0.190 |
Why?
|
| Ontario | 1 | 2021 | 15 | 0.190 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 137 | 0.180 |
Why?
|
| Potassium | 1 | 2021 | 66 | 0.180 |
Why?
|
| Sodium | 1 | 2021 | 64 | 0.180 |
Why?
|
| Nerve Block | 1 | 2021 | 67 | 0.180 |
Why?
|
| Sex Factors | 2 | 2020 | 475 | 0.180 |
Why?
|
| Peptides | 1 | 2021 | 103 | 0.180 |
Why?
|
| Walking | 1 | 2023 | 259 | 0.170 |
Why?
|
| Movement Disorders | 1 | 2021 | 90 | 0.170 |
Why?
|
| Biomarkers | 2 | 2020 | 596 | 0.170 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 212 | 0.170 |
Why?
|
| Residence Characteristics | 2 | 2012 | 214 | 0.160 |
Why?
|
| Functional Laterality | 1 | 2019 | 62 | 0.160 |
Why?
|
| Linear Models | 1 | 2020 | 251 | 0.160 |
Why?
|
| Apolipoproteins E | 1 | 2020 | 252 | 0.160 |
Why?
|
| Noncommunicable Diseases | 1 | 2018 | 2 | 0.160 |
Why?
|
| Heredity | 1 | 2018 | 7 | 0.160 |
Why?
|
| Depression | 1 | 2023 | 452 | 0.160 |
Why?
|
| Pedigree | 1 | 2018 | 67 | 0.160 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 307 | 0.150 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2018 | 1 | 0.150 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 146 | 0.150 |
Why?
|
| Glycogen | 1 | 2018 | 16 | 0.150 |
Why?
|
| ROC Curve | 4 | 2022 | 144 | 0.150 |
Why?
|
| Milk | 1 | 2017 | 14 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2019 | 439 | 0.150 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 13 | 0.140 |
Why?
|
| CADASIL | 1 | 2017 | 1 | 0.140 |
Why?
|
| Menopause | 1 | 2018 | 99 | 0.140 |
Why?
|
| Research Design | 1 | 2018 | 207 | 0.140 |
Why?
|
| Genotype | 1 | 2018 | 359 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 122 | 0.140 |
Why?
|
| alpha-Synuclein | 1 | 2018 | 132 | 0.140 |
Why?
|
| Vasodilation | 1 | 2016 | 5 | 0.140 |
Why?
|
| Feasibility Studies | 1 | 2017 | 231 | 0.140 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2016 | 5 | 0.140 |
Why?
|
| Chicago | 1 | 2020 | 939 | 0.140 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2016 | 7 | 0.140 |
Why?
|
| Mutation | 1 | 2018 | 353 | 0.130 |
Why?
|
| Methamphetamine | 1 | 2016 | 23 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 41 | 0.130 |
Why?
|
| Neuropathology | 1 | 2016 | 82 | 0.130 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 46 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 492 | 0.130 |
Why?
|
| Tropanes | 1 | 2015 | 1 | 0.130 |
Why?
|
| Organotechnetium Compounds | 1 | 2015 | 8 | 0.130 |
Why?
|
| Child | 1 | 2020 | 1421 | 0.130 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 28 | 0.130 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 17 | 0.130 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 43 | 0.120 |
Why?
|
| Prediabetic State | 1 | 2014 | 3 | 0.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 80 | 0.120 |
Why?
|
| Heart Rate | 1 | 2014 | 117 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2014 | 13 | 0.110 |
Why?
|
| Body Mass Index | 3 | 2023 | 465 | 0.110 |
Why?
|
| Memory | 1 | 2015 | 302 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2019 | 139 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 191 | 0.100 |
Why?
|
| Rural Population | 1 | 2012 | 25 | 0.100 |
Why?
|
| Urban Population | 1 | 2012 | 157 | 0.090 |
Why?
|
| Quality of Life | 1 | 2016 | 659 | 0.090 |
Why?
|
| Phenotype | 2 | 2023 | 311 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 80 | 0.080 |
Why?
|
| Logistic Models | 1 | 2010 | 395 | 0.080 |
Why?
|
| Efferent Pathways | 1 | 2008 | 1 | 0.080 |
Why?
|
| Neural Conduction | 1 | 2008 | 11 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 735 | 0.080 |
Why?
|
| Action Potentials | 1 | 2008 | 89 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 89 | 0.070 |
Why?
|
| Skin | 1 | 2008 | 116 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2022 | 3609 | 0.070 |
Why?
|
| Middle East | 2 | 2017 | 5 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 500 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 986 | 0.070 |
Why?
|
| Developing Countries | 2 | 2018 | 14 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2017 | 59 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 196 | 0.060 |
Why?
|
| Europe | 2 | 2016 | 66 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2017 | 268 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 239 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 825 | 0.060 |
Why?
|
| Angina, Unstable | 2 | 2014 | 12 | 0.060 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2014 | 14 | 0.060 |
Why?
|
| Prevalence | 2 | 2016 | 467 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 30 | 0.050 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 7 | 0.050 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 7 | 0.050 |
Why?
|
| Olfactory Bulb | 1 | 2023 | 17 | 0.050 |
Why?
|
| Proteome | 1 | 2023 | 42 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 145 | 0.050 |
Why?
|
| Health Surveys | 2 | 2013 | 88 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2021 | 5 | 0.050 |
Why?
|
| Triamcinolone | 1 | 2021 | 5 | 0.050 |
Why?
|
| Lewy Bodies | 1 | 2023 | 194 | 0.050 |
Why?
|
| Lidocaine | 1 | 2021 | 24 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 34 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2021 | 39 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 1 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 119 | 0.050 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 7 | 0.050 |
Why?
|
| Causality | 1 | 2021 | 56 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 53 | 0.050 |
Why?
|
| Young Adult | 2 | 2018 | 2069 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2021 | 269 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2022 | 241 | 0.040 |
Why?
|
| Sleep | 1 | 2023 | 355 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2019 | 6 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2019 | 27 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 16 | 0.040 |
Why?
|
| Anthropometry | 1 | 2019 | 32 | 0.040 |
Why?
|
| Adiposity | 1 | 2019 | 42 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 18 | 0.040 |
Why?
|
| Physical Examination | 1 | 2019 | 118 | 0.040 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2018 | 1 | 0.040 |
Why?
|
| Developed Countries | 1 | 2018 | 4 | 0.040 |
Why?
|
| Mediterranean Region | 1 | 2017 | 3 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 86 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 41 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 99 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 267 | 0.040 |
Why?
|
| Microvessels | 1 | 2017 | 14 | 0.040 |
Why?
|
| Poverty | 1 | 2018 | 100 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 110 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2018 | 96 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2016 | 4 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 18 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2016 | 2 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2016 | 2 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 266 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 76 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 10 | 0.030 |
Why?
|
| Africa | 1 | 2016 | 11 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 40 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 30 | 0.030 |
Why?
|
| International Cooperation | 1 | 2016 | 24 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 19 | 0.030 |
Why?
|
| China | 1 | 2016 | 52 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 331 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 205 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 73 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 25 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2016 | 92 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 75 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 221 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 165 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 309 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 397 | 0.030 |
Why?
|
| United States | 1 | 2021 | 2197 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 372 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 135 | 0.030 |
Why?
|
| Rural Health | 1 | 2013 | 8 | 0.030 |
Why?
|
| Urban Health | 1 | 2013 | 22 | 0.030 |
Why?
|
| Diet | 1 | 2014 | 220 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 19 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 95 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 2307 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 68 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 194 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 129 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 356 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 169 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 3780 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 53 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2008 | 103 | 0.020 |
Why?
|
| Hand | 1 | 2008 | 40 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 243 | 0.020 |
Why?
|